{"id":"NCT02618759","sponsor":"Sun Pharmaceutical Industries, Inc.","briefTitle":"Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-28","primaryCompletion":"2017-03-16","completion":"2017-08-25","firstPosted":"2015-12-01","resultsPosted":"2018-12-10","lastUpdate":"2018-12-10"},"enrollment":119,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"DSXS","otherNames":["Active"]},{"type":"DRUG","name":"Placebo","otherNames":["vehicle"]}],"arms":[{"label":"DSXS1505","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the therapeutic efficacy and safety of DSXS compared to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.","primaryOutcome":{"measure":"Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 Â± 2","timeFrame":"28 Days","effectByArm":[{"arm":"DSXS1505","deltaMin":10,"sd":null},{"arm":"Placebo","deltaMin":3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0745"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":60},"commonTop":["Headache","Vertigo","Application site pain","Application site paraesthesia","Cellulitis"]}}